丙型肝炎病毒实验性疫苗免疫学评价

管洁; 谭文杰

丙型肝炎病毒实验性疫苗免疫学评价

管洁,
谭文杰

中国疾病预防控制中心病毒病预防控制所

基金项目:

国家“863”专题项目(2007AA02Z455)；国家传染病科技重大专项(2009ZX10004-715)；

详细信息

中图分类号: R392
计量
- 文章访问数: 4479
- HTML全文浏览量: 18
- PDF下载量: 1066
- 被引次数: 0
出版历程
- 出版日期: 2011-01-20

The immunological evaluation of hepatitis C virus vaccine

Research funding:

摘要

摘要:
丙型肝炎病毒(HCV)属于黄病毒科,其基因组为单股正链RNA,易变异,慢性感染可导致肝脏慢性炎症坏死和纤维化,部分患者可发展为肝硬化甚至肝细胞癌,对患者的健康和生命危害极大,已成为严重的社会和公共卫生问题,目前尚无有效的疫苗。本文综述了HCV实验性疫苗的免疫学评价方法,为疫苗的研制及应用提供参考。
- 肝炎病毒属 /
- 肝炎,丙型 /
- 病毒性肝炎疫苗 /
- 抗体生成 /
- 免疫,细胞
Abstract:
Hepatitis C virus (HCV) is an enveloped positive-strand RNA virus in the family Flaviviridae with high mutation rate in the genome. Chronic infection causes chronic hepatitis, necrosis and fi brosis, which can progress to cirrhosis and hepatocellular carcinoma which is one of the biggest public heath problem. However, there is no effective vaccine update. The development of HCV vaccine is based on the evaluation of the specifi c immune responses against HCV and protection after challenge.
- hepacivirus /
- hepatitis C /
- viral hepatitis vaccines /
- antibody formation /
- immunity

HTML全文

参考文献(36)

[1]Lindenbach B, Rice C.Unraveling hepatitis C virus replication from genome to function[J].Nature, 2005, 436 (7053) :933-938.

[2]Lavanchy D, Purcell R, Hollinger FB, et al.Global surveillance and control of hepatitis C[J].Viral Hepat, 1999, 6 (1) :35-47.

[3]De Francesco R, Migliaccio G.Challenges and succ-esses in developing new therapies for hepatitis C[J].Nature, 2005, 436 (7053) :953-960.

[4]Lauer GM, Walker BD.Hepatitis C Virus Infection[J].N Engl J Med, 2001, 345 (1) :41-52.

[5]Thimme R, Oldach D, Chang KM, et al.Determinants of viral clearance and persistence during acute hepatitis C virus infection[J].Exp Med, 2001, 194 (10) :1395-1406.

[6]Cooper S, Erickson AL, Adams EJ, et al.Analysis of a successful immune response against hepatitis C virus[J].Immunity, 1999, 10 (4) :439-449.

[7]Lechner F, Wong D, Dunbar P, et al.Analysis of successful immune responses in persons infected with hepatitis C virus[J].J Exp Med, 2000, 191 (9) :1499-1512.

[8]Cox A, Mosbruger T, Lauer G, et al.Comprehensive analyses of CD8+T cell responses during longitudinal study of acute human hepatitis C[J].Hepatology, 2005, 42 (1) :104-112.

[9]Lechner, F.Gruener N, Urbani S, et al.CD8+T lymphocyte responses are included during acute hepatitis C rirus infection but are not sustained[J].Eur J Immunol, 2000, 30 (9) :2 479-2487.

[10]Bassett S, Guerra B, Brasky K, et al.Protective im-mune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection[J].Hepatology, 2001, 33 (6) :1479-1487.

[11]Lanford, R, Guerra B, Chavez D, et al.Cross-genotype immunity to hepatitis C virus[J].J Virol, 2004, 78 (3) :1575-1581.

[12]Thimme R, Oldach D, Chang K, et al.Determinants of viral clearance and persistence during acute hepatitis C virus infection[J].J Exp Med, 2001, 194 (10) :1395-1406.

[13]Shoukry N, Cawthon A, Walker C.Cell-mediated im-munity and the outcome of hepatitis C virus infection[J].Annu Rev Microbiol, 2004, 58:391-424

[14]Ulsenheimer A, Gerlach J, Gruener N, et al.Detection of functionally altered hepatitis C virus-specific CD4+T cells in acute and chronic hepatitis C[J].Hepatology, 2003, 37 (5) :1189-1198

[15]Wedemeyer H, He X, Nascimbeni M, et al.Impaired effector function of hepatitis C virus-speci-c CD8+T cells in chronic hepatitis C virus Infection[J].J Immunol, 2002, 169 (6) :3447-3458.

[16]Appay V, Dunbar P, Callan M, et al.Memory CD8+T cells vary in differentiation phenotype in different persistent virus infections[J].Nat Med, 2002, 8 (4) :379-385.

[17]Choo Q, Kuo G, Ralston R, et al.Vaccination of chi-mpanzees against infection by the hepatitis C virus[J].Proc Natl Acad Sci, 1994, 91 (4) :1294-1298.

[18]Farci P, Shimoda A, Wong D, et al.Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein[J].Proc Natl Acad Sci, 1996, 93 (26) :15394-15399.

[19]Grakoui A, Shoukry N, Woollard D, et al.HCV persistence and immune evasion in the absence of memory T cell help[J].Science, 2003, 302 (5645) :659-662.

[20]Thimme R, Bukh J, Spangenberg H, et al.Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease[J].Proc Natl Acad Sci, 2002, 99 (24) :15661-15668.

[21]Folgori A, Capone S, Ruggeri L, et al.A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees[J].Nat Med, 2006, 12 (2) :190-197.

[22]Grakoui A, Shoukry NH, Woollard DJ, et al.HCV persistence and immune evasion in the absence of memory T cell help[J].Science, 2003, 302 (5645) :659-662.

[23]Neumann C, Thimme R.Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection[J].Genes Immun, 2007, 8 (3) :181-192.

[24]Houghton M, Abrignani S.Prospects for a vaccine against the hepatitis C virus[J].Nature, 2005, 436 (7053) :961-966.

[25]Rosa D, Campagnoli S, Moretto C, et al.A quantitative test to estimate neutralizing antibodies to the hepatitis C virus:cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells[J].Proc Natl Acad Sci, 1996, 93 (5) :1759-1763.

[26]Bartosch B, Dubuisson J, Cosset F.Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1-E2 Envelope Protein Complexes[J].J Exp Med, 2003, 197 (5) :633-642.

[27]Wakita T, Pietschmann T, Kato T, et al.Production of临床肝胆病杂志2011年第27卷第1期infectious hepatitis C virus in tissue culture from a cloned viral genome[J].Nat Med, 2005, 11 (7) :791-796.

[28]Lindenbach B, Evans M, Syder A, et al.Complete replication of hepatitis C virus in cell culture[J].Science, 2005, 309 (5734) :623-626.

[29]Stamataki Z, Coates S, Evans M, et al.Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies[J].Vaccine, 2007, 25 (45) :7773-7784.

[30]Kreher C, Dittrich M, Guerkov R, et al.CD4+and CD8+cells in cryopreserved human PBMC maintain full functionality in cytokine C virus in cell culture[J].Science, 2005, 309 (5734) :623-626.

[31]Diepolder H, Zachoval R, Hoffmann R, et al.Possible mechanism involving T lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection[J].Lancet, 1995, 346 (8981) :1 006-1007.

[32]Rigopoulou E, Suri D, Chokshi S, et al.Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B:antiviral and immunological activity[J].Hepatology, 2005, 42 (5) :1028-1036.

[33]Elmowalid G, Qiao M, Jeong S, et al.Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees[J].Proc Natl Acad Sci, 2007, 104 (20) :8427-8432.

[34]Murata K, Lechmann M, Ming Q, et al.Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection[J].Proc Natl Acad Sci, 2003, 100 (11) :6753-6758

[35]Simon B, Cornell K, Clark T, et al.DNA Vaccination Protects Mice against Challenge with Listeria monocytogenes Expressing the Hepatitis C Virus NS3 Protein[J].Infect Immun, 2003, 71 (11) :6372-6380.

[36]Encke J, Findeklee J, Geib J, et al.Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection[J].Clin Exp Immunol, 2005, 142 (2) :362-369.

施引文献

资源附件(0)

访问统计